The year's 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013's top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma's macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index.
GlaxoSmithKline is the first pharma company to get behind the U.K.'s forthcoming Francis Crick Institute, signing on to lend its minds and molecules to an open R&D effort.
Now that billionaire entrepreneur Patrick Soon-Shiong has taken control of tiny ConkWest and steered it toward a $173 million IPO, he's adding a makeover to the name that will fit more easily under the fast-growing NantWorks umbrella he's created.
Moving on from a painful Phase II failure for its top prospect, Ohr Pharmaceutical heralded new hope for the eye drop in retinal vein occlusion thanks to some positive results from a midstage study.
Otsuka and its partner Lundbeck snagged an FDA approval for Rexulti (brexpiprazole) to treat schizophrenia and as an add-on therapy for major depression, leaving the two companies prepping for an August launch into an increasingly crowded field.
ResearchKit, the technology Apple promises will transform the world's hundreds of millions of iPhones into handheld gatherers of clinical data, could become a viable tool in drug development, and two major drugmakers are working to integrated into clinical trials.
Catheters designed to deliver chemotherapy are often coated in silver to provide an antibacterial coating. But scientists at the Norwegian University of Science and Technology found that this silver actually breaks down chemotherapy drugs and can release a harmful gas, hydrogen fluoride in the process.
The rapid maturation of gene therapy technologies has galvanized a wide range of projects throughout industry and academia, and now a team of researchers from Harvard and Boston Children's Hospital believe they may have come up with a one-time treatment for a genetic cause of deafness.
Sanofi has widened its R&D net, recruiting 7 of the U.S.'s most-respected research institutions in hopes of ferreting out some new ideas in early-stage drug development.
Lawmakers in the House are expected to step up and cast their votes on the 21st Century Cures Act today, a big step toward once again shaking up the legal framework built to guide drug development in the U.S. while significantly boosting the amount of funding that flows to the NIH.